A Phase 3 interventional study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) and Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP) in Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 246 sites in 32 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.
Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2012, is one of 30 in phase 3, and was the 127th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:
The First Hospital of Jilin University · Sites in China
Ages 65+
Paolo Caimi, MD · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Ou Bai, MD/PHD · Sites in China
Ages 70+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 60+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
218 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 146 · Phase 3 32 · Phase 4 3
First in 1993; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 743 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 46 across the 211 interventional studies. Of the 142 that completed or were terminated, 61 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 218 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Lymphoma, Large B-Cell, Diffuse by Hoffmann-La Roche: 2 open now, 5 under way, 1 of them phase 3. Of 22 finished, 13 (59%) have results posted.
Among the 28 studies in Lymphoma, Large B-Cell, Diffuse by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2012, is one of 7 in phase 3, and was the 8th registered.
Hoffmann-La Roche’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2005.
7 of the studies testing rituximab in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06573645Phase 3Xia YiA Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | 2027-01-12 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT04978584M.D. Anderson Cancer CenterRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | 2027-01-16 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Hoffmann-La Roche’s 28 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
This multi-center, open-label, randomized study will evaluate the participant preference with subcutaneous versus intravenous administration of MabThera/Rituxan (rituximab) in participants with CD20+ diffuse large B-cell lymphoma or CD20+ follicular non-Hodgkin's lymphoma. In Arm A, participants will receive MabThera/Rituxan 375 mg/m2 intravenously (IV) on Day 1 of Cycle 1 and MabThera/Rituxan 1400 mg subcutaneously (SC) on Day 1 of Cycles 2-4, followed by MabThera/Rituxan IV in Cycles 5-8. Participants in Arm B will receive MabThera/Rituxan IV in Cycles 1-4 and SC in Cycles 5-8. All participants will receive 6-8 cycles of standard chemotherapy (according to local country practice) with 8 cycles of MabThera/Rituxan. Anticipated time on study treatment is up to 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Arm A received one cycle of rituximab 375 mg/m\^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m\^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) · Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP) · Drug: Bendamustine · Drug: Rituximab
Participants in Arm B received four cycles of rituximab 375 mg/m\^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) · Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP) · Drug: Bendamustine · Drug: Rituximab
Drug pages: Cyclophosphamide · Doxorubicin · Vincristine · Prednisone · Prednisolone
Standard chemotherapy
Drug pages: Cyclophosphamide · Vincristine · Prednisone · Prednisolone
Standard chemotherapy
Standard chemotherapy
Also known as: Treanda
1400 mg subcutaneously (SC), Day 1 Cycles 2-4
Also known as: Rituxan, MabThera
375 mg/m2 IV, Day 1 Cycles 1-4
Also known as: Rituxan, MabThera
375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
Also known as: Rituxan, MabThera
1400 mg SC, Day 1 Cycles 5-8
Also known as: Rituxan, MabThera
Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6
Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6.
Time frame: Cycle 6 (Up to 24 weeks)
Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8
Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing Cycle 8.
Time frame: Cycle 8 (Up to 32 weeks)
Number of Participants With Treatment Emergent Adverse Events (AEs)
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Randomization of first participant to clinical cutoff date (Up to 4 years)
Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])
Administration time was defined as the time from start to end of the SC injection or from start to end of the IV infusion
Time frame: Cycle 1-4, Cycle 5-8 for both SC and IV (Up to 32 weeks)
Cancer Therapy Satisfaction Questionnaire (CTSQ) Score
CTSQ is a validated 16-item questionnaire that measures three domains related to participants' satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
Time frame: During Cycle 4, 8 of treatment (Up to 32 weeks)
Rituximab Administration Satisfaction Questionnaire (RASQ) Score
The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
Time frame: During Cycle 4, 8 of treatment (Up to 32 weeks)
Complete Response (CR) Rate
CR rate was assessed according to the International Working Group (IWG) Response Criteria (CHESON ET AL. 1999) and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by \> 75 % but still \>1.5 cm in size, and indeterminate bone marrow assessment. Tumor assessments were based on computed tomography (CT) scans with contrast of the neck, chest, and abdomen (if detectable by these techniques) or other diagnostic means, if applicable. Other methods (e.g., MRI) were acceptable for participants in whom contrast CT scans were contraindicated. Due to the limited availability of FDG-PET scanners, an FDG-PET scan was not mandated in the study.
Time frame: 28 days (± 3 days) after Day 1 of the last dose of induction treatment
Event-free Survival (EFS)
EFS was defined as the time from randomization to first occurrence of progression or relapse according to IWG response criteria. IWG criteria is defined using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; partial response (PR): At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses; stable disease (SD): participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (PD); PD: Lymph nodes considered abnormal if the long axis is more than 1.5 centimeter (cm) regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes less than or equal to (\<=) 1.0 × \<= 1.0 cm would not be considered as abnormal for PD.
Time frame: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)
Disease-free Survival (DFS)
DFS was defined as the period from the data of the initial CR/CRu until the date of relapse or death from any cause, whichever occurred first.
Time frame: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)
Progression-free Survival (PFS)
PFS was defined as the time from randomization to the first occurrence of progression or relapse, according to the IWG response criteria. IWG criteria is defined criteria using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; PR: At least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses; SD: participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for PD; PD: Lymph nodes considered abnormal if the long axis is more than 1.5 cm regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes \<= 1.0 × \<= 1.0 cm would not be considered as abnormal for PD.
Time frame: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)
Overall Survival (OS)
OS was defined as the time from randomization to death from any cause.
Time frame: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)
Percentage of Participants With Anti-Rituximab Antibodies Over Time
Time frame: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)
Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time
Time frame: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)
Summary of Observed Serum Rituximab Concentration
Time frame: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 371 | 369 |
| Completed | 244 | 236 |
| Not completed | 127 | 133 |
| Withdrew: Adverse event | 11 | 6 |
| Withdrew: Death | 46 | 58 |
| Withdrew: Participant request/ withdrew consent | 18 | 14 |
| Withdrew: Lost to follow-up | 15 | 15 |
| Withdrew: Reason not specified | 36 | 39 |
| Withdrew: Missing | 1 | 1 |
Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6.
| percentage of participants | Arm A | Arm B |
|---|---|---|
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6 | 79.1 (74.2 to 83.5) | 80.6 (75.7 to 84.8) |
Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing Cycle 8.
| percentage of participants | Arm A | Arm B |
|---|---|---|
| Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8 | 77.1 (71.9 to 81.8) | 84.2 (79.6 to 88.2) |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| participants | Arm A | Arm B |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) | 352 | 347 |
Administration time was defined as the time from start to end of the SC injection or from start to end of the IV infusion
| minutes | Rituximab Intravenous (IV) | Rituximab Subcutaneous (SC) |
|---|---|---|
| Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV]) | 840 (0 to 3967.0) | 22 (0 to 1242.0) |
CTSQ is a validated 16-item questionnaire that measures three domains related to participants' satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
| units on a scale | Rituximab Intravenous (IV) | Rituximab Subcutaneous (SC) |
|---|---|---|
| Expectations of therapy domain | 80.88 ± 18.315 | 82.07 ± 17.817 |
| Feelings about side effects domain | 60.63 ± 22.316 | 61.64 ± 22.324 |
| Satisfaction with therapy domain | 84.59 ± 12.218 | 85.42 ± 11.259 |
The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
| units on a scale | Rituximab Intravenous (IV) | Rituximab Subcutaneous (SC) |
|---|---|---|
| Physical impact domain | 82.14 ± 15.629 | 82.08 ± 15.882 |
| Psychological Impact domain | 77.73 ± 16.377 | 84.00 ± 14.358 |
| Impact on activitiesf daily living | 59.49 ± 22.233 | 81.86 ± 15.844 |
| Convenience domain | 59.05 ± 20.757 | 81.05 ± 13.088 |
| Satisfaction domain | 74.88 ± 19.349 | 87.26 ± 14.972 |
CR rate was assessed according to the International Working Group (IWG) Response Criteria (CHESON ET AL. 1999) and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by \> 75 % but still \>1.5 cm in size, and indeterminate bone marrow assessment. Tumor assessments were based on computed tomography (CT) scans with contrast of the neck, chest, and abdomen (if detectable by these techniques) or other diagnostic means, if applicable. Other methods (e.g., MRI) were acceptable for participants in whom contrast CT scans were contraindicated. Due to the limited availability of FDG-PET scanners, an FDG-PET scan was not mandated in the study.
| percentage of participants | Arm A | Arm B |
|---|---|---|
| Complete Response (CR) Rate | 49.2 (43.5 to 54.9) | 52.7 (47.0 to 58.3) |
EFS was defined as the time from randomization to first occurrence of progression or relapse according to IWG response criteria. IWG criteria is defined using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; partial response (PR): At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses; stable disease (SD): participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (PD); PD: Lymph nodes considered abnormal if the long axis is more than 1.5 centimeter (cm) regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes less than or equal to (\<=) 1.0 × \<= 1.0 cm would not be considered as abnormal for PD.
| months | Arm A | Arm B |
|---|---|---|
| Event-free Survival (EFS) | NA (NA to NA) | NA (NA to NA) |
DFS was defined as the period from the data of the initial CR/CRu until the date of relapse or death from any cause, whichever occurred first.
| months | Arm A | Arm B |
|---|---|---|
| Disease-free Survival (DFS) | NA (NA to NA) | NA (NA to NA) |
PFS was defined as the time from randomization to the first occurrence of progression or relapse, according to the IWG response criteria. IWG criteria is defined criteria using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; PR: At least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses; SD: participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for PD; PD: Lymph nodes considered abnormal if the long axis is more than 1.5 cm regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes \<= 1.0 × \<= 1.0 cm would not be considered as abnormal for PD.
| months | Arm A | Arm B |
|---|---|---|
| Progression-free Survival (PFS) | NA (NA to NA) | NA (NA to NA) |
OS was defined as the time from randomization to death from any cause.
| months | Arm A | Arm B |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
| percentage of participants | Arm A | Arm B |
|---|---|---|
| Cycle 1 | 2.0 | 3.0 |
| Cycle 2 | 2.1 | 2.2 |
| Cycle 3 | 0.3 | 0.9 |
| Cycle 4 | 0 | 0.3 |
| Interim staging | 0 | 0 |
| Cycle 5 | 0 | 0 |
| Cycle 6 | 0 | 0 |
| Cycle 7 | 0 | 0 |
| Cycle 8 | 0 | 0 |
| Final staging | 0 | 0 |
| Follow-up, 6 months | 1.8 | 0 |
| Follow-up, 12 months | 2.1 | 0.6 |
| End of study/early treatment termination | 0.6 | 0.6 |
| percentage of participants | Arm A | Arm B |
|---|---|---|
| Cycle 1 | 11.4 | 15.6 |
| Cycle 2 | 7.0 | 18.2 |
| Cycle 3 | 7.1 | 23.5 |
| Cycle 4 | 7.0 | 14.7 |
| Interim staging | 9.0 | 9.7 |
| Cycle 5 | 12.5 | 10.2 |
| Cycle 6 | 16.0 | 11.6 |
| Cycle 7 | 23.8 | 10.9 |
| Cycle 8 | 13.3 | 11.0 |
| Final staging | 10.0 | 12.6 |
| Follow-up, 6 months | 6.5 | 13.4 |
| Follow-up, 12 months | 7.7 | 8.7 |
| End of study/early treatment termination | 3.5 | 6.3 |
| microgram per milliter | Arm A | Arm B |
|---|---|---|
| Cycle 1 | 3355.9 ± 21600.95 | 970.1 ± 9415.93 |
| Cycle 2 | 25053.1 ± 19590.17 | 24541.1 ± 18141.76 |
| Cycle 3 | 62977.0 ± 30037.98 | 46093.9 ± 31214.30 |
| Cycle 4 | 87956.6 ± 40441.84 | 59485.5 ± 29183.17 |
| Interim staging | 117273.6 ± 52227.06 | 77665.3 ± 29161.77 |
| Cycle 5 | 108030.9 ± 54335.08 | 70387.3 ± 30256.48 |
| Cycle 6 | 100927.7 ± 49287.42 | 98679.7 ± 40001.55 |
| Cycle 7 | 95614.0 ± 45499.56 | 117172.0 ± 44501.74 |
| Cycle 8 | 104873.0 ± 50346.69 | 137048.1 ± 53669.39 |
| Final staging | 86806.6 ± 43005.90 | 120995.7 ± 58731.10 |
| Follow-up, 6 months | 7802.9 ± 15672.57 | 8042.9 ± 12247.05 |
| Follow-up, 12 months | 2380.1 ± 8494.06 | 1685.3 ± 6669.84 |
| End of study/early treatment termination | 9302.0 ± 27234.88 | 9553.9 ± 30723.30 |
Collected over Randomization of first participant to clinical cutoff date (Up to 4 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | — | 126/371 (34%) | 318/371 (85.7%) |
| Arm B | — | 116/369 (31.4%) | 317/369 (85.9%) |
| Event | Arm A | Arm B |
|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 31/371 | 30/369 |
| NeutropeniaBlood and lymphatic system disorders | 16/371 | 13/369 |
| PneumoniaInfections and infestations | 12/371 | 9/369 |
| Neutrophil count decreasedInvestigations | 11/371 | 10/369 |
| PyrexiaGeneral disorders | 10/371 | 3/369 |
| AnaemiaBlood and lymphatic system disorders | 3/371 | 5/369 |
| SepsisInfections and infestations | 3/371 | 5/369 |
| LeukopeniaBlood and lymphatic system disorders | 5/371 | 1/369 |
| AstheniaGeneral disorders | 4/371 | 1/369 |
| Lung InfectionInfections and infestations | 3/371 | 3/369 |
| Event | Arm A | Arm B |
|---|---|---|
| NauseaGastrointestinal disorders | 83/371 | 102/369 |
| FatigueGeneral disorders | 69/371 | 91/369 |
| AnaemiaBlood and lymphatic system disorders | 79/371 | 68/369 |
| NeutropeniaBlood and lymphatic system disorders | 51/371 | 70/369 |
| Neutrophil count decreasedInvestigations | 63/371 | 69/369 |
| ConstipationGastrointestinal disorders | 59/371 | 60/369 |
| AlopeciaSkin and subcutaneous tissue disorders | 60/371 | 56/369 |
| VomitingGastrointestinal disorders | 44/371 | 57/369 |
| PyrexiaGeneral disorders | 55/371 | 48/369 |
| DiarrhoeaGastrointestinal disorders | 45/371 | 50/369 |
| Age, Continuous(years) | Arm A | Arm B | Total |
|---|---|---|---|
| Mean | 58.2 ± 13.18 | 59.4 ± 12.64 | 58.8 ± 12.92 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 187 | 180 | 367 |
| Male | 184 | 189 | 373 |
Showing the first 100 of 246 sites across 32 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2012, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Lymphoma, Large B-Cell, Diffuse →